EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system

Agnaldo Lopes da Silva Filho iD, Ricardo Luis Pereira Bueno, Yohanna Ramires iD, Lara Marina Cruz Lino iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0301207 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS ONE, 2024. Verfasst von Agnaldo Lopes da Silva Filho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Faculty, Gynecology Department, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Contraceptive Agents, Female, Intrauterine Devices, Medicated, Desogestrel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORGANON BRASIL.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High rates of unplanned pregnancies persist despite pharmacological developments and advancements in contraceptive methods. Here, we demonstrate that the etonogestrel-releasing subdermal contraceptive implant (IMP-ETN) may be an appropriate and cost-effective alternative to levonorgestrel-releasing intrauterine systems (LNG-IUSs) for women in Brazil. For our pharmacoeconomic analysis, we reviewed the literature on IMP-ETN regarding its acceptance, eligibility criteria, choice, relations with age, adverse events and, finally, the unmet need in the fee-for-service private healthcare sector. We considered qualitative observations in combination with quantitative analysis and performed a deterministic sensitivity analysis to investigate whether this technology can be self-sustainable over a period of five years. The target population for this analysis comprised 158,696 women. Compared with the continued use of LNG-IUSs, adopting the IMP-ETN can result in a cost avoidance of $ 7.640.804,02 in the first year and $ 82,455,254.43 in five years. Disseminating information among physicians will promote this change and strengthen the potential cost avoided by private health system payers. These savings can be used to improve other healthcare programs and strategies. Moreover, the principles of care can be promoted by improving and adapting healthcare systems and expanding treatment and follow-up strategies. This would also provide support to women’s reproductive rights and improve their quality of life. Our results suggest that the IMP-ETN has a favorable cost-effectiveness profile. Given all its advantages and negative incremental cost impact over a period of five years, the IMP-ETN may be a more favorable alternative to LNG-IUSs. Therefore, it should be offered to beneficiaries with a private healthcare plan. This analysis overcomes previous barriers to the use of cost-benefit models, and our results may help balance decision-making by policymakers, technical consultants, and researchers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Contraceptive Agents, FemaleIntrauterine Devices, MedicatedDesogestrelPregnancyFemaleHumansLevonorgestrelBrazilQuality of LifeDelivery of Health Care

Substanzen

etonogestrelLevonorgestrelContraceptive Agents, FemaleDesogestrel

Autor:innen und Institutionen

  • Medicine Faculty, Gynecology Department, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Business Graduate Program of University 9 of July (PPGA-UNINOVE), São Paulo, Brazil.
  • Organon & Co., São Paulo, Brazil.
  • Postgraduate Program in Pharmaceutical Science, Federal University of Paraná, Curiba, Paraná, Brazil.
  • Master's Business Administration in Health Program, Pontifícia Universidade Católica Do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

ORCID-Profile: Agnaldo Lopes da Silva Filho, Yohanna Ramires, Lara Marina Cruz Lino

Förderung

  • ORGANON BRASIL

Zitieren

APA

Lopes da Silva Filho, A., Luis Pereira Bueno, R., Ramires, Y., & Lino, L. M. C. (2024). Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system. PLOS ONE. https://doi.org/10.1371/journal.pone.0301207

Vancouver

Lopes da Silva Filho A, Luis Pereira Bueno R, Ramires Y, Lino LMC. Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system. PLOS ONE. 2024. doi:10.1371/journal.pone.0301207

BibTeX
@article{LopesdaSilvaFilho2024,
  author = {Lopes da Silva Filho, Agnaldo and Luis Pereira Bueno, Ricardo and Ramires, Yohanna and Lino, Lara Marina Cruz},
  title = {Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0301207}
}
Kostenlos starten →